Lexicon Pharmaceuticals price to sales ratio LXRX

Market value divided by revenue over the last twelve months, since 2014.

Today, Oct 23, 2026: 15.2×
10-year median: 12.2×
Against its 10-year history: 66th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.4× to 197×
Peer median: 1.5×

Lexicon Pharmaceuticals' price to sales ratio is 15.2× as of Oct 23, 2026.

That is above its ten-year median of 12.2×, higher than on 66% of days in the last ten years.

Over that time it ranged from 0.4× in Oct 2020 to 197× in Jun 2024.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to sales ratio over time

median 12.2×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	15.2×	5.8×	26.5×
2025	6.3×	4.2×	68.4×
2024	53.5×	48.7×	197×
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	98.6×	13.9×	125×
2020	12.4×	0.4×	12.6×
2019	1.4×	1.1×	15.3×
2018	8.4×	8.4×	14.8×
2017	13.0×	7.7×	21.1×
2016	7.7×	7.7×	48.1×
2015	57.0×	28.9×	174×
2014	168×	157×	189×

Against its peers

Companies in Drug Manufacturers - General nearest Lexicon Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
LXRXLexicon Pharmaceuticals	15.2×
CRMDCorMedix	1.3×
ZVRAZevra Therapeutics	4.3×
IRWDIronwood Pharmaceuticals	1.5×
PBYIPuma Biotechnology	2.5×
COLLCollegium Pharmaceutical	0.9×
ABUSArbutus Biopharma	4.6×
ARVNArvinas	1.5×
AMPHAmphastar Pharmaceuticals	1.5×
OMEROmeros	n/m
PCRXPacira BioSciences	1.9×
Peer median	1.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Lexicon Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.